Home » Posts tagged 'Melissa Sturgess'
Tag Archives: Melissa Sturgess
Ananda Developments #ANA – New appointments at DJT Plants Limited
Ananda is pleased to announce additions to the team within its operating subsidiary, DJT Plants. Since planting of the first seeds in February, operations at site have become more complex and, under the guidance of Stuart Piccaver, the team has been expanded to include:
- Mark Spurdens MBA, BSc, CMgr, FIFST – COO; Mark was previously Operations Director of two large UK horticultural businesses supplying the main supermarket chains. He brings this experience to build DJT Plant’s medical cannabis business. He has a strong track record in building cohesive and effective teams and in developing high care production facilities within complex supply chains.
- Steve Murray BSc, BASIS – Head of Cultivation; Steve was previously managing 1.4Ha of medical cannabis growing in the UK for a cultivator under contract to GW Pharmaceuticals. He has set up and run large scale farming and intensive pharmaceutical grade production systems. His practical experience will be invaluable as DJT Plants moves towards commercial growing, subject to appropriate Home Office licencing.
- Dr. Nigel Gale – Head of Plant Science; Nigel has extensive experience in Good Agricultural and Collection Practice (GACP) and EU-GMP with a proven track record in developing genetics and successfully cultivating for EU markets, including developing top-selling genetic cultivars for both the medical and recreational cannabis markets in Canada. Nigel has moved to the UK from Canada, where he was Head/Director of Cultivation for several Canadian Licensed Producers. During his time in Canada, Nigel regularly managed the cultivation of up to 100,000 cannabis plants. Nigel is also an Associate Editor of Frontiers in Soil Sciences and the International Journal of Plant Biology.
Mark, Steve and Nigel have already commenced work on site and have begun to fine tune both the nutrition and watering regimes for the plants. Each strain has its own needs, and these are now being identified and accounted for. The team is assessing the plants for genetic traits, which can be done visually by an experienced eye by analysing the size and shape of the leaves on each plant.
Preparations are now being made for the movement of plants from the research facility to the multi-chapelles, the structures where DJT Plants will be cultivating in trial commercial conditions. The team is also engaging with DJT Plants’ consultants on the commercial storage and manufacturing facility plans.
Melissa Sturgess, Chief Executive Officer of Ananda commented; “A warm welcome from all of us at Ananda and DJT to Mark, Steve and Nigel. Building a best-in-class multidisciplinary team will be the foundation of our commercial success and we particularly look forward to being able to draw on their vast combined experience where it will matter; excellence in plant science, excellence in practical execution and excellence in managing a complex business with, as I like to say, lots of moving parts. A good strategy is of little use without first class practical execution.”
Corporate
There remains one outstanding item to complete the Circular to shareholders for the purchase of the 50% of DJT Plants not already owned by Ananda. Once final sign off is obtained, the Circular will be posted to shareholders and the General Meeting called.
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Investor Relations |
+44 (0)7463 686 497 ir@anandadevelopments.com |
PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Corporate Broking |
+44 (0)20 7469 0930 |
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
About Ananda Developments
Ananda is an AQSE-listed medical cannabis company creating UK-based operations to grow and provide carbon zero, consistent, medical cannabis for the UK and international markets.
The UK medical cannabis market is predicted to be worth £450m by 2025 and the European market is predicted to be worth USD4.2bn by 2027.
Ananda Developments #ANA – DJT Plants’ Cannabis Flower approved for Israel Import
Ananda, which is creating UK-based operations to grow and provide carbon neutral, consistent, high quality medical cannabis for the UK and international markets, announces that the Government of Israel has granted a licence for cannabis flower grown at Ananda’s subsidiary, DJT Plants Limited (“DJT Plants”) to be imported into Israel. The licence is held by Cannasoul Analytics, the research company which will be analysing DJT Plants’ cannabis flower.
The purpose of obtaining an import licence at this early stage is to ensure that DJT Plants has a clear understanding of all requirements for moving cannabis flower, a controlled drug under the UK Government’s Misuse of Drugs Act 1971, from the UK into Israel. The import licence was awarded by Israel’s Department of Pharmaceutical Import and Narcotics at the Ministry of Health, and by the Ministry of Agriculture and Rural Development Plant Protection and Inspection Services. Appropriate licences will be sought under the relevant UK legislation allowing the export of cannabis flower from the UK nearer to the time of export.
In April 2020, Ananda announced that it would be collaborating with Professor Dedi Meiri, the leading global medical cannabis researcher at The Technion in Israel, to carry out detailed molecular analysis of the strains of cannabis which Ananda proposes to grow and stabilise at DJT Plants.
As part of Ananda’s research plan to stabilise 65 strains of medical cannabis and conduct field trials, future cannabis plant material grown by DJT Plants will be sent to Cannasoul Analytics, an Israel-based commercial research company formed by Professor Dedi Meiri, for analysis of cannabinoid, terpene and flavonoid profiles. It is the view of the Directors of Ananda that Israel continues to be at the forefront of global medical cannabis research and that Israel’s experts have the greatest depth of understanding of the cannabis plant at the molecular level.
Ananda’s ultimate ambition is for DJT Plants to transition to commercial growing of medical cannabis. The Board remains encouraged by progress.
Preparation of documentation continues for the acquisition of the 50% of DJT Group Limited not already owned by Ananda. This work includes the drafting of a range of supporting agreements. Further detail on the proposed acquisition is detailed in the Company’s announcement of 8 June, 2021.
Ananda’s CEO, Melissa Sturgess, commented: “We don’t underestimate the complexity of the work required to grow medical cannabis in the UK. The prize, however, is big; both from a patient care and a financial perspective. Delivering the best quality, consistent medical cannabis medicine to UK and international patients is our clear objective. We continue to work in a focused and diligent manner towards achieving our goals.”
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Investor Relations |
+44 (0)7463 686 497 ir@anandadevelopments.com |
PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Corporate Broking YELLOW JERSEY PR |
+44 (0)20 7469 0930
+44 (0) 7585 953 660 |
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Ananda Developments #ANA – Update on Medical Cannabis Research Growing Facility
Ananda’s ambition is to be a UK-based grower of carbon neutral, consistent, high quality medical cannabis for domestic and international markets. In 2025, the UK medical cannabis market is expected to be worth £450m and the European market is expected to be worth £2.7bn.
HIGHLIGHTS
- Construction works at DJT Plants Limited’s (“DJT Plants”) medical cannabis research growing facility commenced on 4 July 2021
- Dr Hadar Less, DJT Plants’ Chief Grower, has met the UK based construction team on site
- Preparation of documents continues for the acquisition of the 50% of DJT Group Limited (“DJT Group”) not already owned by Ananda
MEDICAL CANNABIS RESEARCH GROWING FACILITY
Since the last update on 25th June 2021, works have commenced on schedule at the UK based research growing facility site. There has been a post-COVID construction boom and although materials costs have risen since the project was originally scoped it is fully funded from Ananda’s current cash reserves. Once construction is complete, DJT Plants will commence planting its first medical cannabis for its research programme. DJT’s ultimate ambition is to transition to commercial growing of medical cannabis. The Board is highly encouraged by progress to date.
Dr Hadar Less, DJT Plants’ Chief Grower, has spent time on site, met with the construction team and scoped out the job description for the Facility Manager who will be recruited to report directly to him.
Dr Less’ expertise is in plant genetics. He was the Agriculture Division Manager at BOL Pharma, CEO of BOL Agrotech and has experience managing large teams. BOL is one of the largest medical cannabis cultivation and production companies in Israel. Israel has a more mature medical cannabis sector than the UK and has, arguably, a medical cannabis prescribing framework that is most like that in the UK in that patients have to have exhausted other forms of medication to be prescribed cannabis. Dr Less was actively involved in the development of DJT Plants’ successful licence application to the Home Office of the UK Government and his experience is directly applicable to DJT’s immediate research initiatives and ultimate commercial growing ambitions.
Ananda’s CEO Melissa Sturgess commented; “Our team grew medical cannabis under contract for GW Pharmaceuticals, providing a great foundation for our ambitions. The first part of our research plan is to stabilise 65 strains of medical cannabis to add to the body of knowledge about growing in UK conditions. We want to create a scientific and operational platform from which we can move to commercial growing.”
Further updates will be provided as plans progress.
ACQUISITION OF 50% OF DJT GROUP NOT ALREADY OWNED BY ANANDA
A circular containing further information and convening a General Meeting to approve, amongst other things, the acquisition by Ananda of the 50% shareholding in DJT Group not currently owned by Ananda, will be sent to Ananda shareholders as soon as possible. A further announcement will be made at that time.
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Investor Relations |
+44 (0)7463 686 497 ir@anandadevelopments.com |
PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Corporate Broking |
+44 (0)20 7469 0930 |
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Ananda Developments #ANA – Issue of Convertible Loan Notes
Ananda announces that the Company has raised £350,000 (gross) and received firm commitments for a further £200,000 (gross) of convertible loan notes (“CLNs”). The CLNs will be convertible into ordinary shares in the Company (“Ordinary Shares”) at a price of 1p per share and will have a fixed life of 2 years. The CLNs bear interest at a rate of 12.5% per annum, which will be rolled up and satisfied by the issue of Ordinary Shares at the end of the 2-year term.
The subscribers are all currently shareholders of the Company.
The proceeds from the issue of CLNs will be used by Ananda’s 50% owned subsidiary DJT Plants Limited (“DJT Plants”) to fund a larger than originally contemplated footprint for its medical cannabis field trials, to fit out the facility with lab equipment, and to secure the long-term services of key technical personnel. DJT Plants was awarded a licence to grow >0.2% THC cannabis for research purposes by the UK Government Home Office in May 2021.
Melissa Sturgess, CEO of Ananda, commented “We believe we have the opportunity to become a significant participant in the medical cannabis sector by supplying UK grown carbon neutral, consistent and high quality flower and oils to the UK and international markets. There is much work to be done and the team is focused on delivering on this vision. Conducting strain stabilisation and field trials research is the first, and possibly the most important, part of the plan.”
Charles Morgan (Chairman of the Company) and Melissa Sturgess (Chief Executive Officer of the Company) have each subscribed for £125,000 of CLNs. In light of their existing interests in the Company, Charles Morgan and Melissa Sturgess have undertaken not to convert any CLNs and have agreed that no Ordinary Shares will be issued to them by way of interest payment, unless such exercise or issue is otherwise permitted by the City Code on Takeovers and Mergers.
DJT Plants is a wholly owned subsidiary of DJT Group Limited, which is owned 50/50 by Ananda’s wholly owned subsidiary, Tiamat Agriculture Limited, and Anglia Salads Limited. On 8 June 2021, Ananda announced that non-binding Heads of Terms had been agreed for the proposed acquisition by Ananda of the 50% shareholding in DJT Plants not currently owned by Ananda. A circular containing further information and convening a General Meeting to approve that acquisition will be sent to Ananda shareholders as soon as possible. A further announcement will be made at that time.
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Investor Relations |
+44 (0)7463 686 497 ir@anandadevelopments.com |
PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Allie Feuerlein Corporate Broking |
+44 (0)20 7469 0930 |
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Ananda Developments #ANA – Final Results
The Directors of Ananda are pleased to present the audited financial; statements of Ananda Developments plc for the year ended 31 January 2021.
Business Review, Development and Performance
The Company was admitted to trading on the Aquis Stock Exchange (‘AQSE’), formerly NEX Exchange Growth Market on 4 July 2018 as an investment vehicle to invest in the developing market for medicinal or therapeutic cannabis. Initially, the Company’s strategy was focused specifically on companies, projects or products in Israel, Canada and the Netherlands, although this strategy was broadened in September 2018 to permit investment in any jurisdiction which has well established laws in relation to medicinal cannabis.
Since the Company was listed in 2018, the directors have pursued their primary objective of creating long term value for Shareholders through the acquisition of strategic stakes in companies in the medicinal cannabis sector which the directors believe have potential for substantial growth. The current investments are:
- a shareholding of 0.90% in iCAN Israel-Cannabis Limited (‘iCAN’), an international cannabis conference platform and cannabis company incubator and advisor. In the year under review, iCAN has expanded its conference platform and increased the number of companies in its incubator group. Since the end of the reporting period, iCAN has transitioned to an online offering to maintain revenue streams during the COVID-19 pandemic. Also, since the end of the period, Ananda converted its convertible debt into additional equity in iCAN.
- 15% interest in Liberty Herbal Technologies Limited (‘LHT’), the 100 per cent owner and developer of hapac®, ready to use sachets of pre-ground dried herbs for portable vaporisers. During the period under review, LHT continued to sell its hap® devices and sachets in Italy. It has also commenced a range of discussions regarding potential collaborations to expand the footprint of the company.
- 50% (via 100% owned Tiamat Agriculture and 50% owned DJT Group Limited) interest in DJT Plants Limited, which has applied to the Home Office of the UK government for a licence to grow medicinal cannabis first for research. Its ultimate objective is to grow medicinal cannabis in the UK for commercial purposes. Subsequent to the end of the period under review the licence was granted.
The Company is very much in its early stages with its investments not yet generating any revenue. The Company has had no revenue for the year and incurred a loss of £495,109.
Statement of Comprehensive Income
31 Jan 2021 | 31 Jan 2020 | ||
£ | £ | ||
Administrative expenses | (496,110) | (375,224) | |
Interest receivable | 114 | 9,056 | |
Loss from operations | (495,996) | (366,168) | |
Other Comprehensive Income | |||
Foreign Exchange Translation Gain/(Loss) | 887 | (8,292) | |
Total comprehensive loss for the year | (495,109) | (374,460) |
Statement of Financial Position
31 Jan 2021 | 31 Jan 2020 | ||
£ | £ | ||
Non-Current assets | |||
Investments | 1,280,618 | 1,287,762 | |
1,280,618 | 1,287,762 | ||
Current assets | |||
Loan Notes | – | 75,878 | |
Trade and other receivables | 12,718 | 56,499 | |
Total current assets | 12,718 | 132,377 | |
Trade and other payables | 462,299 | 191,742 | |
Net current assets | (449,581) | (59,365) | |
Total assets less current liabilities | 831,037 | 1,228,397 | |
Capital and reserves | |||
Share capital | 928,278 | 836,111 | |
Share premium | 689,229 | 689,229 | |
Share options reserve | 447,337 | 441,755 | |
Retained earnings | (1,233,807) | (738,698) | |
Total equity and liabilities | 831,037 | 1,228,397 |
The financial statements were approved and authorised for issue by the Board and were signed on its behalf by:
Melissa Sturgess
Director
5 July 2021
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Investor Relations |
+44 (0)7463 686 497 ir@anandadevelopments.com |
PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Allie Feuerlein Corporate Broking |
+44 (0)20 7469 0930 |
Alan Green talks to Melissa Sturgess, CEO of Ananda Developments #ANA
Alan Green talks to Melissa Sturgess, CEO of Ananda Developments #ANA, a company and platform that allows cannabis investors to gain exposure to the sector. Melissa outlines the company mission and activities, before bring investors up to date on the most recent development with the UK cannabis research facility build. We then look at the company’s investments into ICAN and Hapac, before Melissa provides some key milestones for investors to look out for in the coming months.
Ananda Developments (ANA) – Proposed 100% ownership of DJT Plants Limited
Proposed move to 100% ownership of DJT Plants Limited
The Directors of Ananda announce that non-binding Heads of Terms have been agreed for the proposed acquisition by Ananda of the 50% shareholding in DJT Plants Limited (“DJT Plants”) not currently owned by Ananda (the “Acquisition”).
Ananda intends to become a significant participant in the medicinal cannabis sector as a UK-based grower of consistent, high quality medicinal cannabis for domestic and international markets. The Directors believe that the Acquisition represents a major step towards fulfilling this objective.
HIGHLIGHTS
- On 17 May 2021, DJT Plants was granted a licence to grow >0.2% THC cannabis for research purposes by the UK Government Home Office (the “Licence”)
- DJT Plants is a wholly owned subsidiary of DJT Group Limited (“DJT Group”), which is owned 50/50 by Ananda’s wholly owned subsidiary, Tiamat Agriculture Limited, and Anglia Salads Limited (“Anglia Salads”)
- Consideration for the Acquisition amounts to £7.3 million and will be satisfied by the issue of 790,538,866 ordinary shares of 0.2p each in Ananda (“Ordinary Shares”) to Anglia Salads (the “Vendor”)
- The consideration values each partner’s shareholding in the licence equally. It reflects the Directors’ belief that the Licence represents the majority of Ananda’s current market value and that DJT Plants has the potential to generate significant value and future revenues for the Company
- On completion of the Acquisition, it is proposed that Stuart Piccaver and Simon Goddard, directors of both Anglia Salads and its parent company, JEPCO Limited (“JEPCO”), will join the Board of Ananda as Joint Chief Executive Officer and Chief Financial Officer, respectively
Reason for the Acquisition
The Directors and the Vendor believe that the Acquisition will be mutually beneficial. In particular, they believe that the Acquisition has the potential to deliver the following important advantages:
- captures 100% of the potential commercial growing revenues in Ananda
- ensures that knowhow and developed Intellectual Property is owned by Ananda
- consolidates ownership, management and operation of the Licence and the business in a single entity
- enables working capital requirements to be managed at the DJT Plants’ level
- secures the services of two senior executives with 4 years’ direct experience growing medicinal cannabis in the UK, as well as 30 years of specialist horticultural experience and significant success in horticultural innovation
- secures the growing and agronomic operations services of JEPCO (the 51% owner of Anglia Salads) on a cost-plus basis, meaning Ananda has the ability to execute its strategy on a ‘turn-key’ basis, rather than having to employ, train, manage and retain its own workforce
- gives Ananda immediate access to formal quality systems and procedures which are vital for the cultivation of consistent and high-quality medicinal cannabis
Ananda CEO, Melissa Sturgess, commented:
“Our job now is to stabilise 65 strains of cannabis, conduct research field trials and ready ourselves for the proposed transition to commercial medicinal cannabis growing, subject to further licensing from the Home Office. Stuart has built his agricultural business into the success it is today, as the second largest grower of specialist salad leaves in the UK. He was also responsible for his company’s success growing medicinal cannabis for GW Pharmaceuticals. I look forward to working with him to achieve our objective of being a grower of consistent and high-quality medicinal cannabis for domestic and international markets.”
Incoming Joint-CEO, Stuart Piccaver, commented:
“Following on from the success of obtaining the Home Office licence, it’s now time to turn our vision and plans into reality. I have led 4 significant end to end horticultural developments for blue chip companies in the last 8 years. The basis of these has been to provide solutions to supply chain issues and, as Melissa has commented, one of these was in cannabis. This has given us extensive knowledge on protected growing structures, growing mediums, crop/climate manipulation and the pure practicalities of commercialising various crops. I look forward to joining Melissa and the Ananda team to draw on that experience to ensure our success.”
Background
On 18 May 2021, Ananda announced its 50% owned subsidiary, DJT Plants, had been granted a licence to grow >0.2% THC cannabis for research purposes by the UK Government Home Office. The Licence allows DJT Plants to develop a broad range of cannabis genotypes (“strains”) through a genetic stabilisation and field trials programme, with the goal of growing these genotypes in the UK.
DJT Plants intends to produce a line of 65 stable strains through back crossing six generations from a varied portfolio of 13 seeds that exhibit a range of THC/CBD and other cannabinoid, terpene and flavonoid profiles. The focus will be on strains with metabolic profiles relevant to various health indications which have shown to be receptive to treatment with medical cannabis and for which NICE (the National Institute for Clinical Excellence) has called for further research. They will also be filtered for agronomical traits such as yield and resistance to pathogens, moulds, etc.
The intent is to give DJT Plants a number of its own stable cannabis strains, suitable for growing in UK conditions, with metabolic profiles which have been identified as useful for treating certain medical conditions.
Information on the proposed Directors
On completion of the Acquisition, it is proposed that Stuart Piccaver and Simon Goddard, two highly experienced horticultural, and specifically cannabis cultivation, executives, will join the Board of Ananda.
Stuart Piccaver holds a BSc (Hons) and is a third-generation farmer and CEO of JEPCO and a director of Anglia Salads. With a background and interest in marketing and innovation, he has been the driving force for many of the leading agricultural initiatives and successes of JEPCO and its associated companies.
From a standing start in July 2014, he led the team that proved a concept to grow natural season cannabinoids in the UK, lowering the cost of production by 78%. The project grew 5 hectares under cover to fully assess and master the dynamics of UK production. The project proved its feasibility and created a growing blueprint for a highly scalable production technique.
Simon Goddard is a qualified accountant and has been CFO of JEPCO and Anglia Salads for 19 years. He is responsible for all the strategic, financial and operational aspects of the companies and is also responsible for the Group’s CSR and technical quality standards.
During the initial build-out phase of the Company’s cannabis growing facility, salaries due to Stuart Piccaver and Simon Goddard will be accrued.
Terms of the Acquisition
Pursuant to the proposed terms of the Acquisition, Ananda will acquire the 50 ordinary shares of £1.00 each in DJT Group which it does not currently own, for consideration of £7.3 million, which will be satisfied by the issue of 790,538,866 Ordinary Shares (the “Consideration Shares”), at a deemed price of 0.925p per share (the closing price of Ordinary Shares on 7 June 2021).
The transaction is conditional, amongst other things, on:
- The signing of a legally binding sale and purchase agreement to implement the Acquisition (which will include customary restrictive covenant and non-compete provisions)
- Approval of the Acquisition by Ananda’s shareholders at a general meeting; and
- The receipt of tax advice with respect to certain structural aspects of the transaction
If the Acquisition proceeds to completion on the terms outlined above and no additional Ordinary Shares are issued by the Company in the intervening period, the Vendor will be interested in 790,538,866 Consideration Shares, representing approximately 50% of the Company’s enlarged issued share capital.
Under Rule 9 of the City Code on Takeovers and Mergers (the “Code”), and based on the interest of the Vendor outlined above and on the current issued share capital of Ananda, the allotment of the Consideration Shares will be subject to the Takeover Panel granting the Vendor a waiver of the obligations which would otherwise oblige it to make a general offer to shareholders under Rule 9 of the Code (“Rule 9 Waiver” “Whitewash”); any such Rule 9 Waiver would be subject to the approval of independent shareholders in Ananda at a General Meeting.
There can be no guarantee that such shareholder approval will be obtained or that the Takeover Panel will grant the Rule 9 Waiver required to effect the Acquisition.
DJT Group owns a 100% interest in DJT Plants, which holds the Licence, and 100% of Aristaeus Elements Ltd, a company with certain knowhow about cannabis extraction.
Additional Information
As announced on 18 May 2021, the £300,000 raised by the Company in February 2021 has been allocated to DJT Plants to commence the build out of its research facility at the Licence location. An update on progress will be released in due course.
Ananda continues to hold 2% of the equity in cannabis conference platform and start up adviser iCAN-Israel Limited, and 15% of novel medicinal cannabis vaping technology company Liberty Herbal Technologies Limited. An update on these investments will be released in due course.
General Meeting
A circular containing further information and convening a General Meeting to approve the Acquisition will be sent to Ananda shareholders as soon as possible. A further announcement will be made at that time.
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Investor Relations |
+44 (0)7463 686 497 ir@anandadevelopments.com |
PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Allie Feuerlein Corporate Broking |
+44 (0)20 7469 0930 |
Ananda Developments #ANA – Issue of Equity and Directors’ Interests
As referred to in Ananda’s announcement of 18 May 2021, Charles Morgan (Chairman of the Company) and Melissa Sturgess (Chief Executive Officer of the Company) have each been issued with 100,000,000 ordinary shares of 0.2p each in the Company (“Ordinary Shares”; the “Contingent Consideration Shares”) following the successful grant of a > 0.2% THC Home Office Licence to grow cannabis for research activities.
Application will be made for the Ordinary Shares to be admitted to trading on the Access Segment of the AQSE Growth Market and admission is expected to become effective on 26 May 2021.
Directors’ Interests
Following the issue of the Contingent Consideration Shares, Charles Morgan and Melissa Sturgess are interested in Ordinary Shares as follows:
Current Holding of Ordinary Shares | Issue of Contingent Consideration Shares | New Holding of Ordinary Shares | Percentage interest in Ordinary Shares | |
Charles Morgan | 51,071,781 | 100,000,000 | 151,071,781 | 19.03% |
Melissa Sturgess | 77,724,170 | 100,000,000 | 177,724,170 | 22.39% |
Total Voting Rights
Following this issue, the Company has 793,872,220 Ordinary Shares in issue, each share carrying the right to one vote.
This figure of 793,872,220 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.
Concert Party
Following the issue of the Contingent Consideration Shares, the members of the Concert Party will be interested, in aggregate, in 343,657,607 Ordinary Shares, representing 43.29 per cent of the Company’s enlarged issued share capital. The maximum potential interest of the Concert Party in the voting rights of the Company is set out in the table below:
Concert Party Member | Current Holding of Ordinary Shares | Holding of Warrants | Exercise of Options | Maximum interest in Ordinary Shares following exercise of the Warrants by the Concert Party and the exercise of Options |
Maximum %age interest in voting rights following exercise of the Warrants by the Concert Party and the exercise of Options |
Charles Morgan* | 151,071,781 | 5,530,115 | – | 156,601,896 | 19.03% |
Melissa Sturgess* | 177,724,170 | 8,070,282 | – | 185,794,452 | 22.57% |
Jeremy Sturgess-Smith | 1,700,000 | – | 10,451,389 | 12,151,389 | 1.48% |
Peter Redmond | 8,686,743 | 3,686,743 | – | 12,373,486 | 1.50% |
Michael Langoulant | 4,474,697 | 1,474,697 | – | 5,949,394 | 0.72% |
URA | 216 | 216 | – | 432 | – |
Total Concert Party Holding | 343,657,607 | 362,419,660 | 372,871,049 | 372,871,049 | 45.30% |
Ordinary Shares in Issue | 793,872,220 | 812,634,293 | 823,085,682 | 823,085,682 |
*In addition to the Ordinary Shares set out above, Charles Morgan and Melissa Sturgess have been granted options over 9,282,778 and 9,282,778 Ordinary Shares respectively, pursuant to the Company’s Incentive Scheme. Charles Morgan and Melissa Sturgess have undertaken not to exercise these options unless such exercise is permitted by the Takeover Code.
Words and expressions defined in the circular to shareholders in the Company dated 24 May 2019, which is available on the Company’s website at www.anandadevelopments.com, have the same meaning in this announcement.
Ananda Developments #ANA – Grant of Home Office Licence
The Directors of Ananda announce the following progress regarding Ananda’s vision to become a significant participant in the emerging medicinal cannabis sector:
HIGHLIGHTS
- DJT Plants Limited (“DJT Plants”) has been granted a licence to grow >0.2% THC cannabis for research activities by the UK Government Home Office (the “Licence”).
- The build out of DJT Plants’ research facility to breed and stabilise 65 strains of cannabis will commence immediately, utilising the funds raised by the Company in March 2021.
- DJT Plants is a wholly owned subsidiary of DJT Group Limited (“DJT Group”), which is owned as to 50% by Ananda’s wholly owned subsidiary, Tiamat Agriculture Limited, and as to 50% by Anglia Salads Limited (“Anglia Salads”).
Background
On 14 October 2019, DJT Plants submitted its application for a licence to grow >0.2% THC cannabis for research purposes pursuant to the Misuse of Drugs Act 1971. Following submission of the application, DJT Plants and its advisers have been in a dialogue with the Home Office, local police and the MHRA, amongst others. The regulations around COVID-19 caused a year’s delay in Home Office representatives being able to visit the proposed site of the research activities. When regulations allowed, representatives of the Home Office made a visit to proposed locations on 17 March 2021. DJT Plants received its Licence on 17 May 2021.
Anglia Salads and DJT Plants both held UK Home Office licences to grow >0.2% THC cannabis between 2014 and 2017. They successfully grew up to five hectares of cannabis for GW Pharmaceuticals, in multi-chappelle structures in natural season without any artificial heat or light.
The October 2019 licence application included DJT Plants’ phased strategy to become a significant participant in the emerging medicinal cannabis sector. Phase One is the research phase for which the Licence has been granted. Phase Two, which will be subject to further UK Home Office licensing, is to build out commercial growing and extraction facilities, for some 40 hectares, at the same location.
The Licence received on 17 May 2021 is to develop a broad range of cannabis genotypes through a genetic stabilisation and field trials programme, with the goal of growing these genotypes in the UK.
DJT Plants will produce a line of 65 stable genotypes through back crossing six generations from a varied portfolio of 13 seeds that exhibit a range of THC/CBD and other cannabinoid, terpene and flavonoid profiles. Those genotypes with metabolic profiles relevant to various health indications which have shown to be receptive to treatment with medical cannabis and for which NICE (the National Institute for Clinical Excellence) has called for further research, will also be filtered for agronomical traits such as yield and resistance to pathogens, moulds etc. This will give DJT Plants a number of stable genotypes with a range of metabolic profiles, containing high and low levels of THC and CBD, together with a varied range of other cannabinoids, terpenes and flavonoids.
With a focus on neuropathic pain, epilepsy, Parkinson’s Disease and systemic sclerosis and with reference to the scientific literature, DJT Plants will analyse the metabolic profiles of the stable genotypes (including reference to their non-stable origin – via plants grown from first generation hybrid) including analysis of minor cannabinoids, flavonoids and terpenes. This analysis will be carried out in Israel under procedures and techniques developed by Professor Dedi Meiri of the Technion Israel Institute of Technology. Professor Meiri has established an approach for comprehensive metabolic profiling of phytochemicals in cannabis.
The understanding gained from the analysis and studies as described above, together with insight gained from the scientific literature, will assist in the selection of genotypes that could be grown in Phase 2, subject to further licensing from the Home Office, then manufactured under Good Manufacturing Practice (GMP) with a view to becoming available for prescription by doctors on the General Medical Council list of Specialists.
As part of DJT Plants’ research approach, it will also look to establish extraction, distillation and isolation facilities to manufacture “full spectrum” cannabis products and less than full spectrum products according to the specific combinations of cannabinoids, terpenes and flavonoids identified as being efficacious for particular indications.
Following the research phase, and conditional on UK Home Office licensing, the Directors believe a UK source of high quality consistent medicinal cannabis, such as DJT Plants intends to grow and produce, will be well received, given the growing market for medicinal cannabis and the concerns around consistency and quality expressed by prescribing doctors and patients.
Advantages of growing medicinal cannabis in the UK
Anglia Salads and DJT Plants successfully cultivated medicinal cannabis for GW Pharmaceuticals from 2014 to 2017 in UK natural light and heat conditions. Unlike the high capital and operating cost facilities built in some other jurisdictions, DJT Plants will grow cannabis in multi-chappelle structures with the required light, humidity and heat metrics via 100% natural means. By doing this for GW Pharmaceuticals, DJT Plants achieved one natural growth cycle per annum, with consistent quality and a yield of 700g/m2. DJT Plants’ direct experience growing medical cannabis is that one natural cycle per year achieves better economics and is more environmentally friendly and sustainable than ‘pushing’ the plants to achieve two to three crops per year with the associated high costs.
Build Out of Research Facility
On 15 February 2021, Ananda announced that it had raised £300,000 for the build out of its research facility at the Licence location. As reported to shareholders at the time, these funds were set aside for the build out. DJT Plants will therefore immediately commence the build out and commissioning of the research facility.
Issue of Contingent Consideration Shares
Pursuant to the agreement whereby Ananda acquired Tiamat Agriculture Limited, announced on 24 May 2019 and approved by Ananda’s shareholders on 10 June 2019, Melissa Sturgess and Charles Morgan, Chairman and Chief Executive Officer of the Company, are entitled to be issued 100 million ordinary shares of 0.2p each in Ananda when the Licence is granted. These shares will be issued as soon as practicable, and a further announcement will be made at that time.
Ananda CEO Melissa Sturgess said: “Ananda is extremely excited to achieve this important milestone which allows us to grow and stabilise 65 strains of cannabis and conduct field trials. We also maintain our focus on the future when we hope to legally produce premium UK grown medicinal cannabis for patients who need it.”
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa SturgessInvestor Relations Jeremy Sturgess-Smith |
+44 (0)7463 686 497 ir@anandadevelopments.com |
PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Allie FeuerleinCorporate Broking Lucy Williams Duncan Vasey |
+44 (0)20 7469 0930 |
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.